Lamivudine reduces healthcare resource use when added to zidovudine- containing regimens in patients with HIV infection

PharmacoEconomics

Volumn 15, Issue SUPPL. 1, 1999, Pages 13-22

  Lacey, L ^a   Gill, M J ^b  

^a GLAXOSMITHKLINE   (United Kingdom)

^b Southern Alberta Clinic   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOVIRIDE; PLACEBO; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG COST; FEMALE; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS INHIBITION;

ADULT; AMBULATORY CARE; ANTI-HIV AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEALTH RESOURCES; HIV INFECTIONS; HOSPITALIZATION; HUMANS; LAMIVUDINE; LENGTH OF STAY; MALE; ZIDOVUDINE;

EID: 0032907076     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915001-00002     Document Type: Article

References (21)

1. DELTA Coordinating Committee. DELTA: a randomized double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV infected individuals. Lancet 1996; 348: 283-91
2. Randomized trial of addition of lamivudine or lamivudine plus loviride to zidovudine-containing regimens for patients with HIV-1 infections: the CAESAR trial. Lancet 1997; 349: 1413-21
3. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. BHIVA Guidelines Coordinating Committee. Lancet 1997; 349 (9058): 1086-92
4. Payne N. British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1997; 349: 1837
5. Petrou S, Dooley M, Whitaker L., et al. The economic costs of caring for people with HIV infection and AIDS in England and Wales. Pharmacoeconomics 1996; 9 (4): 332-40
6. Brettle RP, Atkinson Fl, Wilcock J, et al. The cost of health care for HIV-positive patients. Int J STD AIDS 1997; 8: 50-3
7. Fortgang IS, Moore RD. Hospital admissions of HIV infected patients from 1988 to 1992 in Maryland. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 8: 365-72
8. Moore RD, Bartlett JG. Combination antiretroviral therapy in HIV infection: an economic perspective. Pharmacoeconomics 1996; 10 (2). 109-13
9. Eron JJ, Benoit SL, Jemesk J, et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per millimetre. N Engl J Med 1995; 333: 1662-9
10. Staszewski S, Lovedaj C, Picazo JJ, et al. Safety and efficacy of lamivudine-zidovudine combination therapy in zidovudine-experienced patients. JAMA 1996; 276: 111-7
11. Lacey L, Hill A, Mauskopf J. The incidence of opportunistic infections and hospitalisations in HIV patients treated with lamivudine/zidovudine [abstract P37]. 3rd International Congress on Drug Therapy and HIV Iinfection; 1996 Nov 3-7; Birmingham, UK. AIDS 1996; 10 Suppl. 2: S28
12. Anis H, Hogg RS, Wang X, et al. The effect of attenuating CD4 decline on subsequent hospitalisation: potential benefit of viral load driven antiretroviral therapy [abstract 263]. 4th Conference on Retroviral and Opportunistic Infections; 1997 Jan 22-26; Washington DC: 1997: 112
13. Mouton Y, Alfandari S, Valette M, et al. Impact of protease inhibitors on AIDS defining events and hospitalisations in 10 French AIDS reference centres. AIDS 1997 Oct; 11 (12): F101-5
14. Anis AH, Hogg RS, Wang X, et al. Modelling the potential economic impact of viral load driven triple drug combination antiretroviral therapy. Pharmacoeconomics 1998; 13 (6): 697-705
15. Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41 (RR-17): 1-19
16. Mauskopf JA, Lacey LA, Kempel A, et al. The cost effectiveness of treatment with lamivudine and zidovudine compared to zidovudine alone: a comparison of Markov model and trial estimates. Am J Manag Care 1998; 4 (7): 1004
17. Carpenter CCJ, Fischl MA, Hammer SL, et al. Antiviral therapy for HIV infection in 1998. Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998; 280: 78-86
18. Gazzard B, Moyle G, on behalf of the BHIVA Guidelines writing committee. 1998 revision to the British HIV Association guidelines for antiretroviral treatment of HIV seropositive individuals. Lancet 1998; 352: 314-6
19. Chancellor JV, Hill AM, Sabin CA, et al. Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics 1997; 12 (1): 54-66
20. Lacey L, Mauskopf J, Lindrooth R, et al. A prospective cost-consequence analysis of adding lamivudine to zidovudine-containing antiretroviral treatment regimens for HIV infection in the US. Pharmacoeconomics 1999; 15 Suppl. 1: 23-38
21. Lacey L, Youle M, Trueman P, et al. A prospective evaluation of the cost effectiveness of adding lamivudine to zidovudine-containing antiretroviral treatment regimens in HIV infection: European perspective. Pharmacoeconomics 1999; 15 Suppl. 1: 39-53